Actuate Therapeutics Inc
NASDAQ:ACTU · NASDAQ Global Market
+$0.06 today
Vol 0.03M · Avg 0.16M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ACTU · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$21.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.99, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $344.8M | $725.6M | $804.0M |
| Gross Profit | $0 | $0 | $0 | $0 | $10.3B | $8.9B | $7.6B |
| Gross Margin | — | — | — | — | 45.5% | 9.8% | 28.9% |
| Research & Development | $10.3M -44.9% | $18.7M -14.0% | $21.7M +32.5% | $16.4M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $12.2M +88.2% | $6.5M +98.6% | $3.3M -14.5% | $3.8M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $22.5M -10.6% | $25.2M +0.7% | $25.0M +23.6% | $20.2M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $0 -100.0% | $2.1M +685.5% | $272.9K +329.0% | $63.6K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$22.2M +11.7% | -$25.2M -3.0% | -$24.4M -21.7% | -$20.1M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | — | — | — | — | 10.0% | 5.6% | 46.3% |
| Operating Income | -$22.5M +10.6% | -$25.2M -0.7% | -$25.0M -23.6% | -$20.2M | $10.6B | $12.3B | $14.0B |
| Operating Margin | — | — | — | — | 18.7% | 16.6% | 24.1% |
| Interest Income | $287.7K +29.4% | $222.3K -37.0% | $352.7K +1204.9% | $27.0K | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $20.3K +208.2% | -$18.7K -142.9% | $43.6K +169.4% | $16.2K | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $267.5K +112.6% | -$2.1M -1026.6% | $229.2K +383.5% | $47.4K | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$22.2M +18.5% | -$27.3M -10.3% | -$24.7M -22.7% | -$20.2M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | — | — | — | — | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $0 -100.0% | $800 | $0 | $0 | $666.8M | $1.3B | -$1.6B |
| Net Income | -$22.2M +18.5% | -$27.3M -10.3% | -$24.7M -22.7% | -$20.2M | $5.0B | $4.9B | $4.8B |
| Net Margin | — | — | — | — | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$1 +67.5% | -$3 -97.6% | -$2 -23.1% | -$1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$1 +67.5% | -$3 -97.6% | -$2 -23.1% | -$1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $21.0M +7.7% | $19.5M +29.8% | $15.0M +0.0% | $15.0M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $21.0M +7.7% | $19.5M +29.8% | $15.0M +0.0% | $15.0M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Nkarta, Inc.
NASDAQ:NKTX
$195.68M
Alector, Inc.
NASDAQ:ALEC
$174.86M
Molecular Partners AG
NASDAQ:MOLN
$148.22M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$129.13M
PepGen Inc.
NASDAQ:PEPG
$120.70M
Vor Biopharma Inc.
NASDAQ:VOR
$103.52M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$71.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$62.56M
VistaGen Therapeutics, Inc.
VTGN
$22.68M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ACTU generate?
Actuate Therapeutics Inc (ACTU) reported $0.00 of revenue in fiscal 2025.
Is ACTU profitable?
Actuate Therapeutics Inc (ACTU) reported -$22,227,852.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.